Recruiting Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer NCT07233252 Conditions Kidney-sparing, Nab-paclitaxel, PD-1 Inhibitor, +2 more Locations The Second Hospital of Tianjin Medical University — Tianjin, Outside U.S., China View Trial Details
Recruiting Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer NCT07125547 Conditions Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Kidney-sparing, +14 more Locations The Second Hospital of Tianjin Medical University — Tianjin, Outside U.S., China View Trial Details
